CVS Health (CVS) shares have rallied nearly 38% so far this month, driven by the company’s stronger-than-expected first-quarter 2025 results. Despite concerns over the company’s decision to implement widespread store closures due to new Pharmacy Benefit Management (PBM) reform legislation, market sentiment remains positive. Investors are encouraged by the robust performance of CVS Health Care Benefits segment, which benefited from favorable prior-year development and improved Medicare performance. The margi ...

Scientific Advisory Board will bring significant expertise in psilocybin research and clinical trial designNEW YORK, Feb. 26, 2025 (GLOBE NEWSWIRE) -- Psyence Biomedical Ltd. (Nasdaq: PBM) (“Psyence Biomed” or the “Company”) today announced that it will work closely with Albert P. Garcia-Romeu, Ph.D., to chair and develop its newly created Scientific Advisory Board (SAB). Dr. Garcia-Romeu is a leading psychedelics researcher currently serving as Associate Professor in the Department of Psychiatry and Behavi ...

Exhibit 99.3 Psyence Biomedical Ltd. (Formerly the carve-out of Psyence Biomed Corp.) Consolidated Financial Statements For the years ended March 31, 2024 and 2023 Expressed in United States Dollars (USD $) PSYENCE BIOMEDICAL LTD. Consolidated Financial Statements Management's Responsibility for Financial Reporting The accompanying consolidated financial statements of the Company have been prepared by management in accordance with International Financial Reporting Standards. These financial statements conta ...

NEW YORK, Dec. 27, 2024 (GLOBE NEWSWIRE) -- Psyence Biomedical Ltd. (Nasdaq: PBM) (“Psyence Biomed” or the “Company”) today announced that it has closed its previously announced private placement for the purchase and sale of an aggregate of 1,000,000 common shares (or pre-funded warrants in lieu thereof), series A common warrants to purchase up to 1,000,000 common shares and short-term series B common warrants to purchase up to 1,000,000 common shares at a purchase price of $2.00 per common share (or per pr ...

NEW YORK, Dec. 23, 2024 (GLOBE NEWSWIRE) -- Psyence Biomedical Ltd. (Nasdaq: PBM) (“Psyence Biomed” or the “Company“) today announced that it has entered into definitive agreements for the purchase and sale of an aggregate of 1,000,000 common shares (or pre-funded warrant in lieu thereof), series A common warrants to purchase up to 1,000,000 common shares and short-term series B common warrants to purchase up to 1,000,000 common shares at a purchase price of $2.00 per common share (or per pre-funded warrant ...

Company poised to enter 2025 with cash position of $5.6 million and debt-free balance sheetNEW YORK, Dec. 23, 2024 (GLOBE NEWSWIRE) -- Psyence Biomedical Ltd. (Nasdaq: PBM) (“Psyence Biomed” or the “Company”) today announced that it has received notice from the Nasdaq Hearings panel that the Company has regained compliance with all applicable Nasdaq continued listing requirements. As previously announced, Psyence Biomed requested to be transferred from The Nasdaq Global Market to The Nasdaq Capital Market, ...

Patient screening underway; first patient expected to be randomized into the study in January A leading clinical trial site management organization (SMO), Australian Clinical Trial Network (ACTioN), has been engaged to implement patient recruitment and retention strategies NEW YORK, Dec. 17, 2024 (GLOBE NEWSWIRE) -- Psyence Biomedical Ltd. (Nasdaq: PBM) ("Psyence Biomed" or the "Company") today highlighted recent progress that has been made with its active Phase IIb clinical trial of nature derived psiloc ...

Company Overview - CVS Health (NYSE: CVS) has experienced a significant stock price decline to $49 due to concerns over PBM (Pharmacy Benefit Manager) reform following an FTC lawsuit alleging abusive practices such as rebate retention and price manipulation [1] - PBMs contribute nearly half of CVS's operating income, making the company highly sensitive to regulatory changes in this area [1] Industry and Regulatory Impact - The FTC lawsuit has raised fears about potential reforms in the PBM industry, which could significantly impact CVS's profitability given its heavy reliance on PBM operations [1] Analyst Background - Yiannis Zourmpanos, founder of Yiazou IQ, is an experienced analyst with a background in auditing and consulting at Deloitte and KPMG [1] - Zourmpanos holds professional qualifications including Chartered Certified Accountant and Fellow Member of ACCA Global, with BSc and MSc degrees from UK business schools [1] - The analyst's investment style focuses on GARP/Value stocks, prioritizing high-quality businesses with strong moats and growth potential, trading at a discount to intrinsic value with a margin of safety [1] - The investment approach emphasizes long-term wealth accumulation (5-7 years) through compounding, downside protection, and sometimes taking contrarian views during market uncertainties [1]

UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 Table of Contents (Mark One) ☐ REGISTRATION STATEMENT PURSUANT TO SECTION 12(b) OR 12(g) OF THE SECURITIES EXCHANGE ACT OF 1934 OR ☒ ANNUAL REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the fiscal year ended March 31, 2024 OR ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(D) OF THE SECURITIES EXCHANGE ACT OF 1934 OR Commission File Number: 001-41937 Psyence Biomedical Ltd. | --- | --- | --- | |----- ...